BGNE

BeiGene Ltd
D

BGNE

177.320
USD
0.87
(0.49%)
Market Open
Volume
2,072
EPS
-6
Div Yield
-
P/E
-22
Market Cap
18,878,946,012
OverviewSignalsIdeasNews
Related Instruments
    ALNY
    ALNY
    -7.535
    (-3.07%)
    237.970 USD
    A
    ARCT
    1.160
    (7.48%)
    16.660 USD
    C
    CRSP
    -0.520
    (-1.28%)
    40.200 USD
    E
    EDIT
    -0.05000
    (-3.79%)
    1.27000 USD
    I
    INCY
    0.110
    (0.16%)
    69.020 USD
    MRNA
    MRNA
    0.310
    (0.79%)
    39.670 USD
    REGN
    REGN
    5.80
    (0.83%)
    708.40 USD
    T
    TBIO
    0
    (0%)
    0.000000 USD
    VRTX
    VRTX
    1.11
    (0.28%)
    398.26 USD
    More
News

Title: BeiGene Ltd

Sector: Healthcare
Industry: Biotechnology
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies witha contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.